- Home
- ANGX vs PHAR Comparison
ANGX vs PHAR Comparison
Compare ANGX & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGX | PHAR |
|---|---|---|
| Founded | 2013 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 989.8M | 793.4M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ANGX | PHAR |
|---|---|---|
| Price | $4.88 | $10.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $9.75 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 1.8M | 28.2K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $321,558,306.00 | N/A |
| Revenue This Year | $46.23 | $10.04 |
| Revenue Next Year | $25.81 | $2.51 |
| P/E Ratio | ★ N/A | $3,041.22 |
| Revenue Growth | ★ 233.16 | N/A |
| 52 Week Low | $2.05 | $9.62 |
| 52 Week High | $9.85 | $21.34 |
Technical Indicators
Market Signals| Indicator | ANGX | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | N/A |
| Support Level | $3.90 | N/A |
| Resistance Level | $5.58 | N/A |
| Average True Range (ATR) | 0.34 | 0.00 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 27.20 | 0.00 |
Price Performance
Historical ComparisonAbout ANGX Angel Studios Inc.
Angel Studios Inc is an entertainment company known for crowd-funded films and television projects. It enables creators to share projects and engage audiences directly. The platform allows fans to invest in and promote productions, fostering a community-driven approach to content creation.
About PHAR Pharming Group N.V.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.